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Implication for health policy/practice/research/medical education:
Knowing the prevalence and antibiotic resistance pattern of extended spectrum beta lactamase producing Escherichia coli as the 
most common urinary tract infection pathogen, in addition to alert to health system policymakers about increasing antibiotics 
resistance, helps therapists to prescribe appropriate antibiotics to treat them.
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Introduction: Urinary tract infection (UTI) due to extended spectrum beta-lactamase 
(ESBL)-producing bacteria including Escherichia coli has become widespread. Studies have 
shown a trend toward higher mortality, longer hospitalization, greater hospital expenses and 
reduced rates of clinical and microbiologic response in ESBL UTI.
Objectives: The aim of this study is to determinate the prevalence and antibiotic resistance 
pattern of ESBL producing E. coli isolated from UTI.
Patients and Methods: This cross-sectional study was conducted on 3126 samples. Urine 
specimens were cultured on Eosin Methylene Blue (EBM) and blood agar. The disk diffusion 
standard method (Kirby Bauer) was used to test the susceptibility of the drug on Muller-
Hinton agar plates and results were reviewed based on Clinical and Laboratory Standards 
Institute (CLSI) criteria. The reviewing of ESBL-producing uropathogens was carried 
out using Combined Disk Test (CDT) by using cefotaxime (CTX; 30 µg) and cefotaxime- 
clavulanic acid (CTX; 30 µg /CA:10 µg) disks and CLSI protocol.
Results: Out of 291 E. coli isolates, 108 (37.11%) are ESBL-producer and 183 (62.89%) are 
non–ESBL-producer. Among ESBL-producing E. coli, the highest antibiotic resistance was 
observed with cefotaxime (100%), amoxicillin (97.22%) and piperacillin (96.3%) and the 
highest antibiotic sensitivity was observed with meropenem (93.5%), nitrofurantoin (81.48%) 
and gentamicin (55.56%).
Conclusion: We recommended that cephalosporins, penicillins and cotrimoxazole are not 
suggested in the treatment of ESBL-producing E. coli. On the other hand, carbapenems as a 
first line and aminoglycosides as the next step in the treatment of ESBL-producing E. coli are 
recommended. 
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Urinary tract infection (UTI) is one of the most common
infectious disease that affects about more than 150 
million people every year  (1). Escherichia coli is the most 
common urinary tract pathogen, accounting for 50% to 
90% of UTI isolates (2). E. coli  as an enterobacteriaceae 
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member is gram negative and facultative anaerobic 
bacterium (3). β-lactam antibiotics (beta-lactam 
antibiotics) are the commonly prescribed antibiotics for 
UTI. Beta-lactam antibiotics are a class of broad-spectrum 
antibiotics, consisting of all antibiotic agents that contain 
a beta-lactam ring in their molecular structure (4). Beta-
lactamases are enzymes that hydrolyze beta-lactam ring, 
inactivating the antibiotic (5). Extended-spectrum beta-
lactamase (ESBL) are enzymes that confer resistance to 
most common beta-lactam antibiotics such as penicillins, 
cephalosporins and monobactam (6). ESBL-producing 
bacteria were first reported in 1983, and now infection due 
to ESBL-producing bacteria including E. coli has become 
widespread (7). Studies have shown a trend toward higher 
mortality, longer hospitalization, greater hospital expenses 
and reduced rates of clinical and microbiologic response 
in ESBL UTI (8,9).
Objectives
The aim of this study is to determinate the prevalence and 




This cross-sectional study was conducted on all urine 
samples (3126 samples) sent to the cultivating to the 
central laboratory of Tohid hospital in Sanandaj from 
October 2016 to September 2017. 
Intervention and biochemical measurements
Urine specimens were collected from the midstream urine 
samples in sterile containers and by using a calibrated 
loop (0.01 mL), they were cultured in sterile conditions 
on Eosin Methylene Blue (EBM). The Blood agar and 
then samples were examined at 37°C after 18-24 hours 
incubation. The samples that number of colonies grown on 
their culture medium were more than 105 CFU/mL were 
examined as a positive urine culture to identify genus and 
bacterial species based on standard methods. After the 
final diagnosis, the disk diffusion standard method (Kirby 
Bauer) was used to test the susceptibility of the drug on 
Muller-Hinton agar plates. Creating or not creating and 
the size of inhibition zone around the disk were reviewed 
based on the Clinical and Laboratory Standards Institute 
(CLSI) criteria. The most commonly used antibiotics in 
UTIs were reviewed in studied antibiogram. The reviewing 
of ESBL-producing uropathogens was carried out using 
Combined Disk Test (CDT) and CLSI protocol. At first, 
a microbial suspension equivalent to half McFarland was 
prepared from pure bacterial culture and it was cultured 
on Muller-Hinton agar medium by sterile swab. Then, the 
cefotaxime (CTX; 30 µg) and cefotaxime-clavulanic acid 
(CTX; 30 µg /CA; 10 µg) disks were placed at the distance 
of at least 2.5 cm from each other in medium. After 24 
hours of incubation at 37°C, producing ESBL was studied. 
If the inhibition zone around the cefotaxime-clavulanic 
acid was equal 3 mm or it was greater than inhibition zone 
around cefotaxime, that bacteria was considered as ESBL 
producing. 
Ethical issues
The study was in accordance with the Declaration of 
Helsinki and all participants gave their informed consent 
to enter the study. The study  was approved by the Research 
Committee and the Ethical Committee of the Kurdistan 
University of Medical Sciences. (Ethic code: IR.MUK.
REC.1397.5014).
Data analysis
The data were analyzed by SPSS 23 software. To compare 
qualitative variables, chi-square test was applied. Level of 
significance was P < 0.05. 
Results
Of 3126 studied urine samples, the results of 708 cultures 
(22.64%) were positive. Among uropathogens, E. coli was 
the most common bacteria (41.10%). On the other hand, 
163 bacteria (23.02%) produced ESBL (Figure 1). Out of 
291 E. coli isolates, 108 (37.11%) are ESBL-producer and 
Figure 1. The frequency of ESBL-producing bacteria.
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183 (62.89%) are non–ESBL-producer.
According to the result of antibiogram, the highest 
antibiotic resistance among ESBL-producing E. coli 
was observed with cefotaxime (100%), amoxicillin 
(97.22%) and piperacillin (96.3%). The highest antibiotic 
sensitivity among ESBL-producing E. coli was observed 
with meropenem (93.5%), nitrofurantoin (81.48%) and 
gentamicin (55.56%) (Figure 2).
Discussion
This study showed that 163 (23.02%) bacteria isolated 
from urinary culture were ESBL-producing. Out of 291, 
E. coli isolates, 108 (37.11%) are ESBL-producer and 
183 (62.89%) are non–ESBL-producer. Other studies 
reported a prevalence of ESBL-producer E. coli isolates 
46.87% (10), 82.6% (11) and 21.4% (12) respectively. This 
different results may be due to the difference in the risk 
factors include recent antibiotic therapy, administration of 
corticosteroids, hospitalization (13).
According to the result of antibiogram, the highest 
antibiotic resistance among ESBL-producing E. coli was 
observed with cefotaxime (100%), amoxicillin (97.22%) 
and piperacillin (96.3%). The highest antibiotic sensitivity 
was observed with meropenem (93.5%), nitrofurantoin 
(81.48%) and gentamicin (55.56%). This study showed 
that ESBL-producing E. coli were resistant to penicillins 
and cephalosporins and sensitive to carbapenem, 
nitrofurantoin and aminoglycoside. Our findings are 
similar to other studies (14-16) (Table 1).
Conclusion
Given the dramatic increase in the prevalence of ESBL-
producing E. coli and its consequences, including higher 
mortality, longer hospitalization, greater hospital expenses 
and reduced rates of clinical and microbiologic response, 
evaluation of their prevalence and antibiotic resistance 
pattern are recommended. According to the results of our 
study, it is recommended that cephalosporins, penicillins 
and cotrimoxazole are not administered in the treatment of 
ESBL-producing E. coli. On the other hand, carbapenems 
as a first line and aminoglycosides as the next step in the 
treatment of ESBL-producing E. coli are recommended.
Limitations of the study
The limitation of this study was that the standard and 
correct method is the MIC method, while this method has 
Figure 2. Antimicrobial resistance pattern of ESBL-producing E. coli.
Table 1. Comparison of results of studies
This study Yadav et al (14) Gngane et al (15) Fernando et al (16)
Antibiotic resistance
Cefotaxime (100%) Cephalexin (78.86%) Ampicillin (100%) Ceftriaxone (100%)
Amoxicillin (97.22%) Nalidixic acid (73.98%) Cotrimoxazole (93.80%) Ceftazidime (100%)
Piperacillin (96.30%) Cotrimoxazole (71.54%) Nalidixic acid  (89.70%) Ciprofloxacin (90.10%)
Antibiotic sensitive
Meropenem (93.50%) Imipenem (62.60%) Imipenem (100%) Meropenem (96.10%)
Nitrofurantoin (81.48%) Amikacin (60.97%) Piperacillin-Tazobactam (88.10%) Imipenem (73.70%)
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not been used in this study.
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